NCT02549417View on ClinicalTrials.gov

Phase 3 Study of KHK7580

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 29, 2015

Primary Completion Date

December 22, 2016

Study Completion Date

December 22, 2016

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

KHK7580

Oral administration

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT02549417 - Phase 3 Study of KHK7580 | Biotech Hunter | Biotech Hunter